The Bristol-Myers Squibb Foundation today announced a collaboration with the World Health Organization's (WHO) Stop TB Department for a two-year pilot initiative to strengthen community based prevention, care and control of tuberculosis (TB) including co-infection with HIV in South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo.

AstraZeneca today announced a $200 million investment in a new manufacturing facility, located in China Medical City (CMC), Taizhou, Jiangsu province. The new site, which represents AstraZeneca's largest ever investment in a single manufacturing facility globally, will produce both intravenous and oral solid medicines for the company's growing business in China.

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM).

Boehringer Ingelheim and Gilead Sciences, Inc. (Nasdaq: GILD) have entered into a licensing agreement, under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV.

Pfizer Inc. announced an agreement with Puma Biotechnology, Inc. for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer.

Abbott has begun enrolling U.S. patients in the EXCEL (Evaluation of XIENCE PRIME™ or XIENCE V® versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial.

Merck KGaA announced that it signed two agreements for collaboration of its Merck Serono division with Ono Pharmaceutical Co., Ltd., Osaka, Japan to strengthen its multiple sclerosis and cancer franchises.